Intervacc Ab

Tripep Ab

Alfa Laval Agri International Aktiebolag

Biostapro Ab

Guss, Bengt

Flock, Jan-ingmar

Bergman, Rune

Flock, Margareta

Janzon, Kenneth

Jacobsson, Karin

Frykberg, Lars

Jan-Ingmar Flock

Bengt Guss

Lars Frykberg

Margareta Flock

Karl Olov Zachrisson

Matti Sällberg

Martin K Lindberg

Karin Jacobsson

Rune Bergman

Martin Nilsson

Maria K Bod&eacute;n W&auml;stf&auml;lt

Kenneth Janzon

The present disclosure relates to immunogenic polypeptides, immunogenic compositions and vaccine compositions and use thereof for immunization of mammals susceptible toinfection. The disclosure also relates to methods for preparing, formulating and administrating such compositions.

Vaccine againstinfection

The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both ofsubsp.and subsp.and use thereof for immunization of non-human mammals againstsubsp.and/or subsp.. The present invention also discloses a vaccine composition comprising the aforesaid antigenic composition as immunizing component.

Immunizing composition

An antigenic composition comprises several antigenic components derived from antigens ofsubsp.or subsp., wherein at least one component is a fusion protein or polypeptide compromising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals againstsubsp.and/or subsp.. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.

Vaccine against streptococcal infections based on recombinant proteins

An antigenic composition comprises several antigenic components derived from antigens ofsubsp.or subsp., wherein at least one component is a fusion protein or polypeptide comprising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals againstsubsp.and/or subsp.. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.

The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both ofsubsp.and subsp.and use thereof for immunization of non-human mammals againstsubsp.and/or subsp.. The present invention also discloses a vaccine composition comprising the aforesaid antigenic composition as immunizing component. The antigens used are EAG, FNZ, SFS, SEC and ScLC.

[object Object]

A new fibrinogen binding protein or polypeptide originating from coagulase negativebiotechnological methods for producing the protein or polypeptide having fibrinogen binding activity and a recombinant DNA molecule coding for the protein (or fragments thereof), and micro-organisms (including viruses) containing this recombinant DNA molecule. The present invention further comprises the therapeutic and diagnostic use of the protein and/or DNA, e.g., a diagnostic kit for determining the presence and/or type of coagulase negativeand a vaccine composition, comprising the protein or DNA.

Antibodies to a fibrinogen binding protein of staphylococcus epidermidis

Specificity exchangers and methods of making and using specificity exchangers are disclosed. Specificity exchangers are useful for preventing and treating human diseases including cancer and those resulting from pathogens such as bacteria, yeast, parasites, fungus, viruses, and the like. More specifically, specificity exchangers can redirect existing antibodies in a subject to pathogens and cancer cells.

Specificity exchangers that redirect antibodies to bacterial adhesion receptors

Methods of immunization by administering fibrinogen binding protein or fragments thereof

Growing community of inventors

Bromma, Sweden

Jan-Ingmar Flock